Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation

Nayan Lamba, Malia McAvoy, Vasileios K. Kavouridis, Timothy R. Smith, Mehdi Touat, David A. Reardon, J. Bryan Iorgulescu
doi: https://doi.org/10.1101/2020.03.29.20046805

Data Availability

Availability of data and material: Data are publicly available by application to the American College of Surgeons in accordance with the National Cancer Database’s data use agreement. Code availability: Available upon request.

Back to top
Posted April 01, 2020.
Download PDF
Data/Code
Email
Short-term outcomes associated with temozolomide vs. PCV chemotherapy for 1p/19q-codeleted WHO grade III anaplastic oligodendrogliomas: a national evaluation
Nayan Lamba, Malia McAvoy, Vasileios K. Kavouridis, Timothy R. Smith, Mehdi Touat, David A. Reardon, J. Bryan Iorgulescu
medRxiv 2020.03.29.20046805; doi: https://doi.org/10.1101/2020.03.29.20046805
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area